Endothelial Colony-Forming Cells in Patients With VWD, AVWS and Healthy Subjects

Inclusion Criteria16

• Patients with von Willebrand disease (VWD) or acquired von Willebrand syndrome (AVWS)
• Age ≥ 16 years.
• Previous diagnosis of von Willebrand disease or acquired von Willebrand syndrome, defined as one of the following:
• Group A - Type 1 VWD:
• VWF levels ≤ 30 IU/dL, regardless of bleeding history, or
• VWF levels ≤ 0.50 IU/mL in the presence of abnormal bleeding.
• Group B - Congenital or acquired VWD (VWD or AVWS):
• Diagnosis of congenital or acquired VWD, with or without gastrointestinal bleeding.
• Group C - Subgroup study (Type 2A VWD):
• One patient with type 2A VWD selected for a dedicated sub-study involving allele-specific siRNA silencing of the mutant allele.
• Ability and willingness to provide written informed consent.
• For patients without prior molecular characterization: willingness to undergo VWF gene sequencing and to sign the related informed consent.
• No prior diagnosis of VWD, bleeding disorders, or thrombotic disorders.
• Willingness to donate blood for study procedures.
• Ability and willingness to provide written informed consent.
• Age ≥ 18 years.